Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 9/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | ESRRG | P62508 | 11/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506003 | 0.88 | GAA (0.57) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523669 | 0.87 | ESRRB (0.65) | ESRRBESR1ESR2ESRRGKDM1A | |
| SCHEMBL17523975 | 0.84 | NPC1 (0.59) | ESRRBGAAESRRGKDM1ANPC1 | |
| SCHEMBL17523667 | 0.82 | CYP19A1 (0.50) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523663 | 0.81 | CYP19A1 (0.55) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523660 | 0.80 | ESRRG (0.53) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523670 | 0.80 | CYP19A1 (0.54) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523658 | 0.80 | ESRRG (0.53) | ESRRBGAACYP19A1ESR1ESR2 | |
| SCHEMBL17523662 | 0.78 | EPHX1 (0.51) | GAACYP19A1ESR1ESR2ESRRG | |
| SCHEMBL19182067 | 0.77 | CYP19A1 (0.65) | ESRRBGAACYP19A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | THE PENN STATE RESEARCH FOUNDATION | 2017-08-03 | — | — | US | disclosed |
| WO-2016022325-A1 | NOVEL TRIARYLETHYLENE COMPOUNDS AND METHODS USING SAME | THE PENN STATE RESEARCH FOUNDATION (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217914-A1 | Novel Triarylethylene Compounds and Methods Using Same | CYP46A1, GSTA2, GSTA1 | ESRRB 116/4885GAA 253/4885CYP19A1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.